PL3191511T3 - Ulepszone czynniki wiążące TNF - Google Patents

Ulepszone czynniki wiążące TNF

Info

Publication number: PL3191511T3
Authority: PL; Poland
Prior art keywords: tnf binders; improved tnf; improved; binders; tnf
Prior art date: 2015-11-12

Application number

PL16798122T

Other languages

English (en)

Inventor

Marie-Ange Buyse

Joachim Boucneau

Peter Casteels

Heeke Gino Van

Original Assignee

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-12

Filing date

2016-11-14

Publication date

2018-03-30

2016-11-14 Application filed by Ablynx Nv filed Critical Ablynx Nv

2018-03-30 Publication of PL3191511T3 publication Critical patent/PL3191511T3/pl

Links

239000011230 binding agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Treatment Of Liquids With Adsorbents In General (AREA)
Organic Insulating Materials (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

PL16798122T 2015-11-12 2016-11-14 Ulepszone czynniki wiążące TNF PL3191511T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562254375P	2015-11-12	2015-11-12
PCT/EP2016/077595 WO2017081320A1 (en)	2015-11-12	2016-11-14	Improved tnf binders
EP16798122.4A EP3191511B1 (en)	2015-11-12	2016-11-14	Improved tnf binders

Publications (1)

Publication Number	Publication Date
PL3191511T3 true PL3191511T3 (pl)	2018-03-30

Family

ID=57348648

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16798122T PL3191511T3 (pl)	2015-11-12	2016-11-14	Ulepszone czynniki wiążące TNF

Country Status (36)

Country	Link
US (2)	US10544211B2 (pl)
EP (2)	EP3266798A3 (pl)
JP (2)	JP6962915B2 (pl)
KR (2)	KR20240029115A (pl)
CN (1)	CN108473563B (pl)
AU (2)	AU2016352943B2 (pl)
BR (1)	BR112018009714A8 (pl)
CA (2)	CA3234178A1 (pl)
CL (1)	CL2018001291A1 (pl)
CO (1)	CO2018005915A2 (pl)
CR (1)	CR20180311A (pl)
CY (1)	CY1120303T1 (pl)
DK (1)	DK3191511T3 (pl)
DO (1)	DOP2018000122A (pl)
EC (1)	ECSP18042569A (pl)
ES (1)	ES2662418T3 (pl)
GT (1)	GT201800095A (pl)
HK (1)	HK1248716A1 (pl)
HR (1)	HRP20171949T1 (pl)
HU (1)	HUE035805T2 (pl)
IL (2)	IL310373A (pl)
LT (1)	LT3191511T (pl)
MA (1)	MA41653A (pl)
MD (1)	MD3191511T2 (pl)
ME (1)	ME02954B (pl)
MX (1)	MX2018005992A (pl)
NO (1)	NO2768984T3 (pl)
PE (1)	PE20181317A1 (pl)
PH (1)	PH12018501025A1 (pl)
PL (1)	PL3191511T3 (pl)
PT (1)	PT3191511T (pl)
RS (1)	RS56676B1 (pl)
SG (1)	SG11201803975SA (pl)
SI (1)	SI3191511T1 (pl)
TN (1)	TN2018000159A1 (pl)
WO (1)	WO2017081320A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723769B2 (en)	2011-06-23	2022-06-15	Ablynx NV	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SI3248986T1 (sl)	2014-05-16	2022-04-29	Ablynx Nv	Variabilne domene imunoglobulina
NO2768984T3 (pl) *	2015-11-12	2018-06-09
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
EP4069293A1 (en)	2019-12-06	2022-10-12	Ablynx N.V.	Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
CN114981300A (zh)	2019-12-06	2022-08-30	艾伯霖克斯公司	包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
CN112300289B (zh) *	2019-12-30	2022-06-10	中国药科大学	RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
JP2023553694A (ja) *	2020-12-18	2023-12-25	アブリンクスエン．ヴェー．	ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
WO2024097571A1 (en) *	2022-11-04	2024-05-10	St. Jude Children's Research Hospital, Inc.	Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
WO2024133935A1 (en)	2022-12-23	2024-06-27	Ablynx Nv	Protein-based conjugation carriers
US20240368250A1 (en)	2023-02-17	2024-11-07	Ablynx N.V.	Polypeptides binding to the neonatal fc receptor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69334258D1 (de)	1992-08-21	2009-02-26	Univ Bruxelles	Immunoglobuline ohne Leichtkette
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU2152299A (en)	1997-10-27	1999-05-24	Unilever Plc	Multivalent antigen-binding proteins
KR20010034512A (ko)	1998-02-19	2001-04-25	베렌슨, 론	림프구 활성화 조절을 위한 조성물 및 그 방법
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
NZ540195A (en)	2002-11-08	2009-01-31	Ablynx Nv	Stabilized single domain antibodies
CN101412759A (zh)	2003-01-10	2009-04-22	埃博灵克斯股份有限公司	治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
DK1639011T3 (da)	2003-06-30	2009-02-16	Domantis Ltd	Pegylerede enkelt-domæne antistoffer (dAb)
DE60334645D1 (de)	2003-11-07	2010-12-02	Ablynx Nv	Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
CA2583017A1 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
KR20070086896A (ko)	2004-12-02	2007-08-27	도만티스 리미티드	항ｉｌ1ｒ1 단일 도메인 항체 및 치료적 용도
SG184709A1 (en) *	2005-05-18	2012-10-30	Ablynx Nv	Improved nanobodies™ against tumor necrosis factor-alpha
KR101414438B1 (ko)	2005-05-20	2014-07-10	아블린쓰 엔.브이.	폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
DE102005023617A1 (de) *	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
JP5049973B2 (ja)	2005-08-30	2012-10-17	アクトジェニックス・エヌブイ	慢性全腸炎の治療のための、抗−ＴＮＦα産生乳酸菌
TW200730539A (en)	2005-12-01	2007-08-16	Domantis Ltd	Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
EA200801166A1 (ru)	2005-12-01	2008-12-30	Домантис Лимитед	Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
FR2894741B1 (fr)	2005-12-08	2009-12-04	Centre Nat Etd Spatiales	Chaine de reception par satellite
CA2640066A1 (en)	2006-01-24	2007-08-02	Roland Beckmann	Fusion proteins that contain natural junctions
CA2666599A1 (en)	2006-08-18	2008-02-21	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101611056A (zh)	2006-12-05	2009-12-23	埃博灵克斯股份有限公司	能够结合于血清蛋白的肽
KR101264473B1 (ko)	2007-05-24	2013-05-29	아블린쓰 엔.브이.	Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
WO2009068625A2 (en)	2007-11-27	2009-06-04	Ablynx N.V.	Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
DE102008023620A1 (de)	2008-05-15	2009-11-19	Mettler-Toledo (Albstadt) Gmbh	Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
EP2285833B1 (en)	2008-05-16	2014-12-17	Ablynx N.V.	AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
JP2012517818A (ja) *	2009-02-19	2012-08-09	グラクソグループリミテッド	改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト
AU2010233658B2 (en)	2009-04-10	2013-11-28	Ablynx Nv	Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
WO2010130832A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
JP2012532620A (ja)	2009-07-16	2012-12-20	グラクソグループリミテッド	改良型抗血清アルブミン結合単一可変ドメイン
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
CN103917560B (zh)	2011-03-28	2017-05-24	埃博灵克斯股份有限公司	双特异性抗‑cxcr7免疫球蛋白单可变结构域
EP2723771B1 (en)	2011-06-23	2019-09-11	Ablynx NV	Serum albumin binding proteins
EP2723769B2 (en) *	2011-06-23	2022-06-15	Ablynx NV	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2987806A3 (en)	2011-08-17	2016-07-13	Glaxo Group Limited	Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
SI3248986T1 (sl)	2014-05-16	2022-04-29	Ablynx Nv	Variabilne domene imunoglobulina
NO2768984T3 (pl)	2015-11-12	2018-06-09
AU2017216864B2 (en) *	2016-02-12	2023-06-22	Ablynx Nv	Method for the production of immunoglobulin single variable domains

2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active Search and Examination
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en not_active Withdrawn
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Application Filing
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en active Application Filing
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 CA CA3005085A patent/CA3005085A1/en active Pending
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active IP Right Grant
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 MX MX2018005992A patent/MX2018005992A/es unknown
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/zh unknown
- 2017-12-15 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
2018
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending

Also Published As

Publication number	Publication date
EP3191511A1 (en)	2017-07-19
KR20240029115A (ko)	2024-03-05
PH12018501025A1 (en)	2019-01-28
CA3234178A1 (en)	2017-05-18
US20170190769A1 (en)	2017-07-06
IL259269A (en)	2018-07-31
ES2662418T3 (es)	2018-04-06
GT201800095A (es)	2019-08-15
PT3191511T (pt)	2017-11-30
CL2018001291A1 (es)	2018-09-14
HRP20171949T1 (hr)	2018-01-26
IL259269B2 (en)	2024-07-01
SG11201803975SA (en)	2018-06-28
DK3191511T3 (en)	2018-01-08
CO2018005915A2 (es)	2018-06-20
AU2016352943B2 (en)	2022-10-20
AU2016352943A1 (en)	2018-06-07
JP2022020666A (ja)	2022-02-01
JP6962915B2 (ja)	2021-11-10
MA41653A (fr)	2018-01-09
US9745372B2 (en)	2017-08-29
HK1248716A1 (zh)	2018-10-19
BR112018009714A2 (pt)	2018-11-21
IL310373A (en)	2024-03-01
EP3266798A3 (en)	2018-03-28
CN108473563B (zh)	2022-06-14
TN2018000159A1 (en)	2019-10-04
US20170267752A1 (en)	2017-09-21
MD3191511T2 (ro)	2018-03-31
EP3191511B1 (en)	2017-09-20
WO2017081320A1 (en)	2017-05-18
SI3191511T1 (en)	2018-01-31
EP3266798A2 (en)	2018-01-10
LT3191511T (lt)	2018-01-10
DOP2018000122A (es)	2018-09-30
RU2018120524A3 (pl)	2020-09-24
CN108473563A (zh)	2018-08-31
ECSP18042569A (es)	2018-07-31
HUE035805T2 (en)	2018-05-28
PE20181317A1 (es)	2018-08-14
CY1120303T1 (el)	2019-07-10
RU2018120524A (ru)	2019-12-13
IL259269B1 (en)	2024-03-01
US10544211B2 (en)	2020-01-28
CA3005085A1 (en)	2017-05-18
AU2023200113A1 (en)	2023-02-16
ME02954B (me)	2018-07-20
BR112018009714A8 (pt)	2019-02-26
JP7357038B2 (ja)	2023-10-05
CR20180311A (es)	2018-10-18
KR102641194B1 (ko)	2024-02-26
NO2768984T3 (pl)	2018-06-09
KR20180083382A (ko)	2018-07-20
JP2019506839A (ja)	2019-03-14
RS56676B1 (sr)	2018-03-30
MX2018005992A (es)	2019-01-31

Publication	Publication Date	Title
HK1254952A1 (zh)	2019-08-02	Ctla4結合劑
IL259269A (en)	2018-07-31	Enhanced TNF-binding agents
HK1245235A1 (zh)	2018-08-24	固體形式
PL3146010T3 (pl)	2024-03-25	Środki wiążące
SI3237350T1 (sl)	2020-02-28	Izboljšano vezivo
GB201518594D0 (en)	2015-12-02	Solid formation
GB201412335D0 (en)	2014-08-27	Binder
GB201610063D0 (en)	2016-07-27	Binders
SI3341334T1 (sl)	2020-12-31	Polprevodniško vezivo
PL3386753T3 (pl)	2020-06-29	Rakiel
GB2537722B (en)	2018-01-10	Booklet
PL3256331T3 (pl)	2020-07-27	Dokument
GB201413311D0 (en)	2014-09-10	Book
SI3393992T1 (sl)	2020-07-31	Vezivo, ki vsebuje oksoogljik
GB201520104D0 (en)	2015-12-30	Scraper
ZA201801356B (en)	2019-07-31	Firelighter
SI3341335T1 (sl)	2020-12-31	Polprevodniško vezivo
GB201418800D0 (en)	2014-12-03	TIO2-Latex composite binder
HRP20181700T1 (hr)	2019-03-08	Fascikl
ZA201707980B (en)	2019-05-29	Binding folder
GB201518350D0 (en)	2015-12-02	Binding rings
FI12481U1 (fi)	2019-10-15	Kiinteä fraktio
GB201503832D0 (en)	2015-04-22	Inamo big book V3
GB201413567D0 (en)	2014-09-17	Binding surfaces
GB201419717D0 (en)	2014-12-17	Binder additive